ivabradine prolonged release
/ Abbott
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 04, 2020
Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study.
(PubMed, Cardiol Ther)
- "Ivabradine PR was found to be non-inferior to ivabradine IR in the management of patients with stable CHF, with a comparable safety profile. Once-daily ivabradine PR effectively maintained the HR in patients shifted from the ivabradine IR twice-daily regimen, and thus may aid in improving treatment compliance."
Clinical • Head-to-Head • Journal • P3 data • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 1
Of
1
Go to page
1